Thousands of women with advanced breast cancer could be denied life-extending drugs because of the “unfair” way they are ...

Enhertu is already approved for more advanced cases of HER2-positive breast cancer, as well as a string of other oncology indications, and made $3.75 billion in sales last year while adding ...

PITTSBURGH — Some 264,000 women will get a breast cancer diagnosis this year, with 50% to 60% of them having a type of cancer called HER2 low. That means the tumors have low levels of the HER2 ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

A mum from Banbury with breast cancer said a life-extending drug would be 'worth it', as a charity speaks out on the 'unfair' ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The study, published Tuesday in The Lancet Oncology, focused on women under 55 with and without a uterus. CBS News medical ...

Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

Breast cancer is one of the most common cancers among women in the United States. Thanks to decades of fundamental research, ...